


In re Application of: Peter ASSAF et al
 Serial No.: 10/555,664
 Filed: November 4, 2005
 Office Action Mailing Date: August 16, 2010

Examiner: Sun Jae Y. Loewe
 Group Art Unit: 1626
 Attorney Docket: 30724
 Confirmation No.: 9895

In the claims:

1-5. (Canceled)

6. (Previously Presented) An NO-donating compound having the general formula I:



Formula I

wherein:

A is selected from the group consisting of alkyl, amine, aryl, C-amide, carbonyl, hydrazine, N-amide and any combination thereof, or absent;

X is a heteroaryl selected from the group consisting of benzodioxole, benzothiophene, diazole, dithiolane, furan, imidazole, indole, phthalazine, piperidine, pyrazine, pyrazole, pyridine, pyridinyl, pyrimidine, pyrrolidine, quinoline and thiadiazole;

B is an ethylene chain;

Y is -ONO₂; and

Z is methyl.

7-16. (Canceled)

17. (Previously presented) The NO-donating compound of claim 6, wherein said heteroaryl is pyridine.

18-31. (Canceled)

In re Application of: Peter ASSAF et al
 Serial No.: 10/555,664
 Filed: November 4, 2005
 Office Action Mailing Date: August 16, 2010

Examiner: Sun Jae Y. Loewe
 Group Art Unit: 1626
 Attorney Docket: 30724
 Confirmation No.: 9895

32. (Previously Presented) An NO-donating compound selected from the group consisting of:

3-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazole-2-yl]-pyridine (**Pet-12**);

2-Chloro-3-[4-methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-6-trifluoromethyl-pyridine (**Pet-18**);

Diethyl-{3-[4-methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyridin-4-yl}-amine (**Pet-19**);

2-Methyl-5-[4-methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyridine (**Pet-20**);

3-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyridine 1-oxide (**Pet-21**);

5-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-2-trifluoromethyl-pyridine (**Pet-22**);

2-Methoxy-6-[4-methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyrazine (**Pet-23**);

Methyl-{6-[4-methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyrazin-2-yl}-amine (**Pet-24**);

2-Ethyl-4-[4-methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyridine 1-oxide (**Pet-25**);

5-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-2-trifluoromethyl-pyridine 1-oxide (**Pet-26**);

3-(4-Amino-2-methyl-pyrimidin-5-ylmethyl)-4-methyl-5-(2-nitrooxy-ethyl)-thiazol-3-ium; chloride (**Pet-68**);

2-Furan-2-yl-4-methyl-5-(2-nitrooxy-ethyl)-thiazole (**Pet-69**);

4-Methyl-5-(2-nitrooxy-ethyl)-2-thiophen-2-yl-thiazole (**Pet-71**);

2-Benzo[b]thiophen-2-yl-4-methyl-5-(2-nitrooxy-ethyl)-thiazole (**Pet-72**);

[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyridin-3-ylmethyl-amine (**Pet-80**);

4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyridine (**Pet-81**);

2-(3,5-Dimethyl-pyrazol-1-yl)-4-methyl-5-(2-nitrooxy-ethyl)-thiazole (**Pet-83**);

In re Application of: Peter ASSAF et al
 Serial No.: 10/555,664
 Filed: November 4, 2005
 Office Action Mailing Date: August 16, 2010

Examiner: Sun Jae Y. Loewe
 Group Art Unit: 1626
 Attorney Docket: 30724
 Confirmation No.: 9895

5-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-1H-imidazol-4-ylamine (**Pet-84**);
 4-Methyl-5-(2-nitrooxy-ethyl)-2-thiophen-2-ylmethyl-thiazole (**Pet-86**);
 4-Methyl-5-(2-nitrooxy-ethyl)-2-(1-thiophen-2-yl-ethyl)-thiazole (**Pet-87**);
 [4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-thiophen-2-yl-methanone (**Pet-88**);
 4-Methyl-5-(2-nitrooxy-ethyl)-2-(nitrooxy-thiophen-2-yl-methyl)-thiazole (**Pet-95**);
 2-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyrazine (**Pet-125**);
 2-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyrazine 4-oxide (**Pet-126**);
 2-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyrazine 1,4-dioxide (**Pet-127**);
 2-Ethyl-5-[4-methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-pyridine (**Pet-144**);
 4-Methyl-5-(2-nitrooxy-ethyl)-thiazole-2-carboxylic acid N'-phthalazin-1-yl-hydrazide (**Pet-153**);
 N-[4-methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-nicotinamide (**Pet-154**);
 N-[4-methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-1-oxy-nicotinamide (**Pet-156**);
 4-Methyl-5-(2-nitrooxy-ethyl)-thiazole-2-carboxylic acid pyridin-3-ylamide (**Pet-170**);
 3-[4-Methyl-5-(2-nitrooxy-ethyl)thiazol-2-ylmethyl]-1H-indole (**Pet-172**);
 [4-Methyl-5-(2-nitrooxy-ethyl)-2-yl]-pyridin-4-yl-amine (**Pet-174**); and
 4-{4-[4-Methyl-5-(2-nitrooxy-ethyl)-thiazol-2-yl]-phenyl}-[1,2,3]thiadiazole (**Pet-178**).

33. (Previously presented) A pharmaceutical composition comprising, as an active ingredient, the NO-donating compound of claim 6 and a pharmaceutically acceptable carrier.

In re Application of: Peter ASSAF et al
Serial No.: 10/555,664
Filed: November 4, 2005
Office Action Mailing Date: August 16, 2010

Examiner: Sun Jae Y. Loewe
Group Art Unit: 1626
Attorney Docket: 30724
Confirmation No.: 9895

34-64. (canceled)

65. (Previously presented) A medical device comprising the NO-donating compound of claim 6 and a delivery system configured for delivering said NO-donating compound to a bodily site of a subject.

66. (Original) The medical device of claim 65, wherein said NO-donating compound forms a part of a pharmaceutical composition, said pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

67. (Original) The medical device of claim 65, wherein said delivering is effected by inhalation.

68. (Original) The medical device of claim 67, wherein said delivery system is selected from the group consisting of a metered dose inhaler, a respirator, a nebulizer inhaler, a dry powder inhaler, an electric warmer, a vaporizer, an atomizer and an aerosol generator.

69. (Original) The medical device of claim 65, wherein said delivering is effected transdermally.

70. (Original) The medical device of claim 69, wherein said delivery system is selected from the group consisting of an adhesive plaster and a skin patch.

71. (Original) The medical device of claim 65, wherein said delivering is effected topically.

72. (Original) The medical device of claim 71, wherein said delivery system is selected from the group consisting of an adhesive strip, a bandage, an

In re Application of: Peter ASSAF et al
Serial No.: 10/555,664
Filed: November 4, 2005
Office Action Mailing Date: August 16, 2010

Examiner: Sun Jae Y. Loewe
Group Art Unit: 1626
Attorney Docket: 30724
Confirmation No.: 9895

adhesive plaster, a wound dressing and a skin patch.

73. (Original) The medical device of claim 65, wherein said delivering is effected by implanting the medical device in a bodily organ.

74. (Original) The medical device of claim 73, wherein said delivery system is selected from the group consisting of an aortic aneurysm graft device, an atrioventricular shunt, a catheter, a defibrillator, a heart valve, a hemodialysis catheter, a hemodialysis graft, an indwelling arterial catheter, an indwelling venous catheter, a needle, a pacemaker, a pacemaker lead, a patent foramen ovale septal closure device, a stent, a stent graft, a suture, a synthetic vascular graft, a thread, a tube, a vascular anastomosis clip, a vascular aneurysm occluder, a vascular clip, a vascular prosthetic filter, a vascular sheath and a drug delivery port, a venous valve and a wire.

75. (Original) The medical device of claim 73, wherein said organ is selected from the group consisting of a pulmonary cavity, a blood vessel, an artery, a vein, a capillary, a heart, a heart cavity and a visceral organ.

76. (Previously Presented) A pharmaceutical composition comprising, as an active ingredient, the NO-donating compound of claim 32 and a pharmaceutically acceptable carrier.

77. (Previously Presented) A medical device comprising the NO-donating compound of claim 32 and a delivery system configured for delivering said NO-donating compound to a bodily site of a subject.

78. (Previously Presented) The medical device of claim 77, wherein said NO-donating compound forms a part of a pharmaceutical composition, said pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

In re Application of: Peter ASSAF et al
Serial No.: 10/555,664
Filed: November 4, 2005
Office Action Mailing Date: August 16, 2010

Examiner: Sun Jae Y. Loewe
Group Art Unit: 1626
Attorney Docket: 30724
Confirmation No.: 9895

79. (Previously Presented) The medical device of claim 77, wherein said delivering is effected by inhalation.

80. (Previously Presented) The medical device of claim 79, wherein said delivery system is selected from the group consisting of a metered dose inhaler, a respirator, a nebulizer inhaler, a dry powder inhaler, an electric warmer, a vaporizer, an atomizer and an aerosol generator.

81. (Previously Presented) The medical device of claim 77, wherein said delivering is effected transdermally.

82. (Previously Presented) The medical device of claim 77, wherein said delivering is effected topically.

83. (Previously Presented) The medical device of claim 77, wherein said delivering is effected by implanting the medical device in a bodily organ.